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diabetic foot infection but our model had several limitations/
assumptions; consequently, the results should be interpreted
cautiously. More clinical studies to evaluate oral antibiotics effec-
tiveness are needed.
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OBJECTIVE: Posaconazole has been demonstrated to be signiﬁ-
cantly superior to standard azole therapy in preventing invasive
fungal infections (IFIs) (P < 0.001) and in reducing overall mor-
tality (P = 0.048) among patients with prolonged neutropenia. In
this study, cost-effectiveness of posaconazole was evaluated from
the Canadian health care system perspective. METHODS: A
trial-based decision analytical model was developed. Patients
were assumed to receive prophylaxis with posaconazole or stan-
dard azole therapy (ﬂuconazole, 81%; itraconazole, 19%). The
probabilities of experiencing an IFI, IFI-related death, and all-
cause mortality over 100 days post treatment were estimated. To
extrapolate results beyond the trial period, the model was
extended to a lifetime horizon using 1-month Markov cycles in
which mortality rate is speciﬁc to the underlying disease as esti-
mated from Statistics Canada and Surveillance, Epidemiology,
and End Result (SEER) data. Pharmacotherapy and treatment
costs associated with IFIs were estimated using published litera-
ture. The model was used to estimate costs, IFIs avoided, life-
years gained, and the incremental cost-effectiveness ratio (ICER)
of posaconazole versus standard azole therapy (2007 Canadian
dollars). RESULTS: Posaconazole is associated with signiﬁcant
fewer IFIs (0.05 vs. 0.11) (P = 0.003), increased life-years (0.744
vs. 0.728), and (excluding costs of the underlying condition)
slightly lower costs ($7147 vs. $7332) per patient relative to
standard azole therapy over a lifetime horizon. A second-order
probabilistic Monte Carlo sensitivity analysis was conducted to
assess the effects of parameter uncertainty, particularly as they
relate to treatment efﬁcacy and the costs of an IFI. Results indi-
cate that there is a 53% probability that posaconazole is cost
saving versus standard azole therapy and a 70% probability that
the ICER for posaconazole is at or below the $50,000 per life-
year saved threshold. CONCLUSION: In addition to the proven
efﬁcacy, posaconazole appeared to be cost saving relative to
standard azole therapy in the prevention of IFIs among high-risk
neutropenic patients.
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OBJECTIVE: Hepatitis C is a disease affecting approximately
180 million people worldwide (WHO 2006) and is one of the
main causes of chronic hepatic disease. HCV infection
progresses to chronic form in 80% of infected individuals.
Approximately 20% progress to cirrhosis over 20 years and,
consequently, a high risk of developing hepatocellular carci-
noma population. We assessed the incremental cost-effectiveness
ratio (ICER) of peginterferon alfa-2a (40 KD) plus ribavirin
(PEG + RBV) versus interferon alfa-2b plus ribavirin
(IFN + RBV) in the treatment of patients with chronic hepatitis
C under the Brazilian payer perspective. METHODS: A
Markov model was built to estimate the clinical and economic
impact related to the incorporation of peginterferon-alfa-2a (40
KD). Clinical stages were based on liver histology, forms of
cirrhotic decompensation, liver cancer and liver transplantation.
A Delphi panel was performed for evaluating the direct medical
resources related to each clinical stage in chronic hepatitis C, as
well as costs from treatment with peginterferon-alfa-2a (40
KD), interferon alfa-2b and ribavirin. Effectiveness of treatment
with peginterferon-alfa-2a (40 KD) was obtained from a mul-
ticenter, controlled, randomized trial involving 1121 naive
patients with chronic hepatitis C (Fried et al, 2002). The model
comprises a life-time horizon. We have assumed a discount rate
of 3% for both costs and outcomes according to international
recommendations (Gold et al, 1996). A sensitivity analysis was
conducted using second-order Monte Carlo simulation. Tested
parameters were costs per stage, treatment costs, discount rate,
response rate to treatment, inﬂation rate and early patient dis-
tribution. RESULTS: The ICER of PEG + RBV versus no treat-
ment was approximately -R$62,521 per quality-adjusted life
year (QALY) gained. The ICER of PEG + RBV versus
IFN + RBV was approximately -R$20,087 per QALY. CON-
CLUSION: The study suggests peginterferon alfa-2a (40 KD)
and ribavirin to be a dominant therapy for treating hepatitis C
in the private health care system in Brazil.
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OBJECTIVE: Tipranavir plus ritonavir (TPV/r) and an optimized
background (OB) antiretroviral regimen delays virologic failure,
reduces viral load and increases CD4 count compared to patients
treated with comparator protease inhibitors, co-administered
with ritonavir (CPI/r) and OB alone. The objective was to inves-
tigate the long-term cost, outcomes and cost-effectiveness of
TPV/r + OB compared to CPI/r + OB in the Canadian health care
system. METHODS: A Markov model was developed and popu-
lated with information on 48-week viral load and CD4 cell count
response from two randomized controlled trials (RESIST 1 and
RESIST 2) and HAART-era published literature. Resource use
and cost data was obtained from a Canadian study and published
sources. Future costs and outcomes were discounted at 5%. The
analysis calculated costs and outcomes from time of starting
these regimens, until 90% of patients in each strategy had died
(lifetime analysis). Cost-effectiveness was calculated as cost per
life year (LY) gained and cost per quality-adjusted life year
(QALY) gained. RESULTS: Total discounted lifetime costs
for TPV/r + OB was $221,541 compared to $194,466 with
CPI + OB. discounted life expectancy and QALYs were greater
for TPV/r + OB compared to CPI/r + OB by 0.530 yrs and
0.516 QALYs, respectively. Incremental cost-effectiveness of
TPR/r + OB was $51,058 per LY gained and $52,517 per QALY
gained. Sensitivity analysis showed results were robust. CON-
CLUSION: TPV/r + OB provides superior clinical improvement
to a population of highly treated HIV patients with limited
treatment options. TPV/r + OB is predicted to improve life
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